AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 214.31B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 6.99B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.48 |
| PE Ratio | 30.87 |
| Forward PE | 17.83 |
| Dividend | 2.44 (1.77%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 3,100,021 |
| Average Volume | 1,919,208 |
| Open | 13,932 |
| Previous Close | 13,820 |
| Day's Range | 13,820 - 13,970 |
| 52-Week Range | 9,574 - 13,970 |
| Beta | 0.17 |
| RSI | 80.74 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows
Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ: AZN), initially established in March 2025. • AZN is in...
AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows
Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ: AZN), initially established in March 2025.
AstraZeneca Shares Leap 9% as Pharma Giant Secures Breakthrough Cancer Drug Approval in UK Market
Anglo-Swedish pharmaceutical giant AstraZeneca plc sparked a frenzy in healthcare shares today, with shares soaring more than 9% to 12,500 pence on the London Stock Exchange after the regulators gave ...
AstraZeneca (AZN) and Harbour BioMed Enhance Biotherapeutics Partnership
AstraZeneca (AZN) and Harbour BioMed Enhance Biotherapeutics Partnership
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discover...
AstraZeneca To Invest $2 Billion In Maryland Manufacturing Expansion
(RTTNews) - AstraZeneca announced plans to invest $2 billion to expand its long-standing manufacturing presence in Maryland. The investment includes a major expansion of the company's flagship biologi...
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk manufacturing expansion, growth plans, next-gen therapies, and more.
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk manufacturing expansion, growth plans, next-gen therapies, and more.
Why AstraZeneca Stock Bumped Higher Today
The company is wasting little time figuring out the particulars of a sweeping capital investment program.
AstraZeneca (AZN) to Invest $2B in U.S. Production Expansion
AstraZeneca (AZN) to Invest $2B in U.S. Production Expansion
AstraZeneca expands U.S. production footprint with $2B investment in Maryland
AstraZeneca (AZN) Plans $2 Billion Expansion in Maryland
AstraZeneca (AZN) Plans $2 Billion Expansion in Maryland
AstraZeneca to invest $2 billion as part of US manufacturing push
AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabil...
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its ...
What's Driving the Market Sentiment Around AstraZeneca PLC?
AstraZeneca PLC's (NYSE: AZN) short interest as a percent of float has risen 34.78% since its last report. According to exchange reported data, there are now 9.55 million shares sold short , which is...
AstraZeneca (AZN) Partners in $120M Pharmaceutical Training Initiative
AstraZeneca (AZN) Partners in $120M Pharmaceutical Training Initiative
Abivax gains amid takeover speculation
Abivax (ABVX) ADRs surge on takeover rumors, with AstraZeneca named as a potential bidder.
FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio
On Thursday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ: AZN)Koselugo (selumetinib) for adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, in...
AstraZeneca Wins FDA Nod For Koselugo In Adult NF1
AstraZeneca Wins FDA Nod For Koselugo In Adult NF1
AstraZeneca's Alexion gets FDA approval for Koselugo
AstraZeneca: Alexion's Koselugo Gets FDA Approval For Adults With Neurofibromatosis Type 1
(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Thursday that the US Food and Drug Administration has approved Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib) for the...
AstraZeneca (AZN) Gains FDA Approval for Koselugo in Neurofibromatosis Type 1
AstraZeneca (AZN) Gains FDA Approval for Koselugo in Neurofibromatosis Type 1
AstraZeneca (AZN) Gains FDA Approval for Koselugo in Adult Treatment
AstraZeneca (AZN) Gains FDA Approval for Koselugo in Adult Treatment
AstraZeneca (AZN) Receives FDA Orphan Drug Designation for Myeloma Treatment
AstraZeneca (AZN) Receives FDA Orphan Drug Designation for Myeloma Treatment
Why biotech and drug stocks are on the mend even though the rest of the market is hurting
Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.